Triple Negative Breast Cancer remains of the most challenging malignancies for both patients and clinicians. Lack of predictive biomarkers makes it the most restrictive breast cancer to treat. Compared to her ER+ and Her2+ counterparts, estrogen axis blockade and Her2 inhibition are not options.
The AKT/MTOR/MAPK pathway has been implicated in cancer cell survival for several decades. Several inhibitors of this pathway have been approved and are in clinical development.
At Pacific Shores Medical Group, we have an open clinical trial that is actively accruing patients that have advanced, unresectable, triple negative breast cancer. The clinical trial will be a combination of an AKT inhibitor, chemotherapy and immunotherapy. They include the investigational compound ipatasertib, paclitaxel and pembrolizumab. Please contact us if you have interest in participating in this clinical trial.